CommentNegative but not futile: MAGE-A3 immunotherapeutic for melanoma
References (10)
Cancer vaccines in the era of checkpoint blockade: the magic is in the adjuvant
Curr Opin Immunol
(2017)- et al.
Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial
Lancet Oncol
(2016) - et al.
The Yin and Yang of T cell costimulation
Science
(1995) - et al.
T-cell help for cytotoxic T lymphocytes is mediated by CD40–CD40L interactions
Nature
(1998) - et al.
A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell
Nature
(1998)
There are more references available in the full text version of this article.
Cited by (6)
Emerging roles of the MAGE protein family in stress response pathways
2020, Journal of Biological ChemistryCitation Excerpt :Since the discovery of MAGEs, a major research focus has been developing MAGE-targeted immunotherapies. Despite promising results from initial clinical trials (14, 15), MAGE-A3 vaccines ultimately failed in Phase III due to a lack of efficacy (16, 17), which suggested that activation of the T-cell response to MAGE-A3 antigen is not sufficient to inhibit disease progression (18). Furthermore, some patients treated with anti-MAGE therapies developed serious off-target effects, like neuro- and cardiotoxicity (19, 20).
Chemotherapy and Physical Therapeutics Modulate Antigens on Cancer Cells
2022, Frontiers in ImmunologyCellular Therapy for Melanoma
2020, Cutaneous Melanoma, Sixth Edition
© 2018 Elsevier Ltd. All rights reserved.